(1) Hospitals and other providers of birth and delivery services or neonatal care to infants shall:
(a) Inform parents or guardians, by providing a departmental information pamphlet or by other means, of:
(i) The purpose of screening newborns for congenital disorders;
(ii) Disorders of concern as listed in WAC 246-650-020(2);
(iii) The requirement for newborn screening;
(iv) The legal right of parents or guardians to refuse testing because of religious tenets or practices as specified in RCW 70.83.020; and
(v) The specimen storage, retention and access requirements specified in WAC 246-650-050.
(b) Obtain a blood specimen for laboratory testing as specified by the department from each newborn no later than forty-eight hours following birth.
(c) Use department-approved newborn screening specimen/information forms and directions for obtaining specimens.
(d) Enter all identifying and related information required on the newborn screening specimen/information form following directions of the department.
(e) In the event a parent or guardian refuses to allow newborn screening, obtain signatures from parents or guardians on the newborn screening specimen/information form.
(f) Forward the newborn screening specimen/information form with dried blood spots or signed refusal to the Washington state public health laboratory so that it will be received no later than seventy-two hours following collection of the specimen, excluding any day that the state laboratory is closed.
(2) Upon receipt of specimens, the department shall:
(a) Record the time and date of receipt;
(b) Perform appropriate screening tests for:
(i) Amino acid disorders;
(ii) Biotinidase deficiency;
(iii) Congenital hypothyroidism;
(iv) Congenital adrenal hyperplasia;
(v) Cystic fibrosis;
(vi) Fatty acid oxidation disorders;
(vii) Galactosemia;
(viii) Guanidinoacetate Methyltransferase (GAMT) deficiency;
(ix) Hemoglobinopathies;
(x) Mucopolysaccharidosis type I (MPS-I);
(xi) Organic acid disorders;
(xii) Pompe disease;
(xiii) Severe combined immunodeficiency (SCID);
(xiv) Spinal muscular atrophy (SMA);
(xv) Urea cycle disorders;
(xvi) X-linked adrenoleukodystrophy (X-ALD).
(c) Report significant screening test results to the infant's attending health care provider or parent or guardian if an attending health care provider cannot be identified; and
(d) Offer diagnostic and treatment resources to health care providers attending infants with significant screening test results within limits determined by the department.
[Statutory Authority: RCW 70.83.050, 70.83.020, and 70.83.030. WSR 25-24-060, s 246-650-020, filed 12/1/25, effective 1/1/26; WSR 20-15-032, § 246-650-020, filed 7/7/20, effective 8/7/20. Statutory Authority: RCW 70.83.050, 70.83.090, and 70.83.020. WSR 19-20-025, § 246-650-020, filed 9/23/19, effective 10/24/19. Statutory Authority: RCW 70.83.050 and 70.83.020. WSR 18-01-024, § 246-650-020, filed 12/8/17, effective 3/1/18. Statutory Authority: Chapter 70.83 RCW. WSR 14-21-017, § 246-650-020, filed 10/2/14, effective 11/2/14. Statutory Authority: RCW 70.83.020. WSR 13-24-072, § 246-650-020, filed 11/26/13, effective 1/1/14. Statutory Authority: Chapter 70.83 RCW. WSR 08-13-073, § 246-650-020, filed 6/16/08, effective 7/17/08. Statutory Authority: Chapters 70.83, 43.20 RCW. WSR 06-04-009, § 246-650-020, filed 1/20/06, effective 2/20/06; WSR 03-24-026, § 246-650-020, filed 11/24/03, effective 12/25/03. Statutory Authority: RCW 43.20.050 and 70.83.050. WSR 92-02-019 (Order 225B), § 246-650-020, filed 12/23/91, effective 1/23/92. Statutory Authority: RCW 43.20.050. WSR 91-02-051 (Order 124B), recodified as § 246-650-020, filed 12/27/90, effective 1/31/91. Statutory Authority: Chapters 43.20 and 70.83 RCW. WSR 91-01-032 (Order 114B), § 248-103-020, filed 12/11/90, effective 1/11/91. Statutory Authority: RCW 43.20.050 and 70.83.050. WSR 87-11-040 (Order 303), § 248-103-020, filed 5/18/87.]